Table 1.
Demographics
| Number | 19 |
| Age (years) | |
| Median | 68 |
| Range | 63–75 |
| Race/ethnicity | |
| White (non-Hispanic) | 18 (95%) |
| American Indian or Alaska Native | 1 (5%) |
| Gleason Score at Prostatectomy | |
| 6 | 1 (5%) |
| 7 | 7 (37%) |
| 8 | 7 (37%) |
| 9 | 4 (21%) |
| T stage | |
| T1 | 1 (5%) |
| T2 | 7 (37%) |
| T3 | 10 (53%) |
| TX | 1 (5%) |
| N stage | |
| N0 | 13 (68%) |
| N1 | 2 (11%) |
| NX | 4 (21%) |
| Prior therapy | |
| Prostatectomy | 19 (100%) |
| Adjuvant/salvage radiation therapy | 16 (84%) |
| Androgen deprivation therapy (<24 months) | 6 (32%) |
| Baseline PSA | |
| Median (ng/mL) | 3.1 |
| Range (ng/mL) | 1.96–10.11 |
| Baseline PSA doubling time | |
| Median (months) | 5.9 |
| 0–3 months | 5 (26%) |
| 3–6 months | 5 (26%) |
| 6–12 months | 6 (32%) |
| >12 months | 3 (16%) |
| Range (months) | 1.1–45.3 |
PSA, prostate-specific antigen.